What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

Novartis submitted data to the US Food and Drug Administration from the PSMAfore study seeking to expand the treatment's ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

"We continue to transform cancer care with Kisqali, building on its established profile in the metastatic setting and now helping a wide range of people as they strive to stay cancer-free ...

Kisqali meanwhile made $480 million last year – finally gathering momentum after a slow start and buoyed by new survival data – and Novartis is waiting on the results of the NATALEE adjuvant ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...

Chemotherapy became popular in the 1970s ... Drugs that act against this target include Ibrance (palbociclib) and Kisqali (ribociclib), both of which are given alongside hormone therapies. A third new ...

Specifically, in a switch strategy, if someone received palbociclib or ribociclib [Kisqali] in the first line ... of time without having to move on to more toxic treatments like chemotherapy. What are ...

LaShae Rolle shares her journey of being diagnosed with a rare breast cancer at the age of 26, making her a part of the less ...